{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:59:05Z","timestamp":1793735945184,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-05838-4","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:39:07Z","timestamp":1743093547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy, safety, and bleeding risk factor analysis of oral anticoagulants in AF patients\u2009\u2265\u200965 years of age: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yanxian","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"5838_CR1","doi-asserted-by":"publisher","unstructured":"Heart Disease andStroke Statistics\u20142023 Update: A Report From the American Heart Association. Circulation. 2023;147:e00\u2013e00. https:\/\/doi.org\/10.1161\/CIR.0000000000001123.","DOI":"10.1161\/CIR.0000000000001123"},{"issue":"3","key":"5838_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1161\/JAHA.113.000250","volume":"2","author":"DE Singer","year":"2013","unstructured":"Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk Score[J]. J Am Heart Association Cardiovasc Cerebrovasc Disease. 2013;2(3):18\u201324. https:\/\/doi.org\/10.1161\/JAHA.113.000250","journal-title":"J Am Heart Association Cardiovasc Cerebrovasc Disease"},{"key":"5838_CR3","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [J]. European Heart Journal: The Journal of the European Society of Cardiology, 2021;42(40):373.","DOI":"10.1093\/eurheartj\/ehaa945"},{"issue":"6","key":"5838_CR4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-Drug interactions of direct oral anticoagulants (DOACs): from Pharmacological to clinical practice. Pharmaceutics. 2022;14(6):1120. Published 2022 May 24.","journal-title":"Pharmaceutics"},{"key":"5838_CR5","first-page":"777","volume":"69","author":"WK Souza","year":"2017","unstructured":"Souza WK, S, B D. Original Investigation. The changing landscape for stroke prevention in AF. Findings from the GLORIA-AF registry phase 2[J]. J Am Coll Cardiol. 2017;69:777.","journal-title":"J Am Coll Cardiol"},{"key":"5838_CR6","doi-asserted-by":"publisher","unstructured":"Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY. GLORIA-AF Investigators. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777\u2013785. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.061. PMID: 28209218.","DOI":"10.1016\/j.jacc.2016.11.061"},{"key":"5838_CR7","doi-asserted-by":"publisher","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J. 2016;ehw210. https:\/\/doi.org\/10.1093\/ejcts\/ezw313","DOI":"10.1093\/ejcts\/ezw313"},{"key":"5838_CR8","doi-asserted-by":"publisher","unstructured":"Hindricks G, Potpara T, Dagres N et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of Cardio-Thoracic surgery (EACTS)[J]. European heart journal, 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","DOI":"10.1093\/eurheartj\/ehaa612"},{"issue":"12","key":"5838_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"issue":"10","key":"5838_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"issue":"11","key":"5838_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"22","key":"5838_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"5838_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. https:\/\/doi.org\/10.1186\/s13063-015-1023-4","journal-title":"Trials"},{"issue":"10","key":"5838_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","volume":"143","author":"JM Franklin","year":"2021","unstructured":"Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT Duplicate initiative. Circulation. 2021;143(10):1002\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051718","journal-title":"Circulation"},{"issue":"3","key":"5838_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1160\/TH11-11-0784","volume":"107","author":"A Banerjee","year":"2012","unstructured":"Banerjee A, Lane DA, Torp-Pedersen C, Lip GYH. Net clinical benefit of new oral anticoagulants (dabigatran, Rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584\u20139. https:\/\/doi.org\/10.1160\/TH11-11-0784","journal-title":"Thromb Haemost"},{"issue":"9","key":"5838_CR16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/M20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim DH, Pawar A, Gagne JJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study. Ann Intern Med. 2021;174(9):1214\u201323. https:\/\/doi.org\/10.7326\/M20-7141","journal-title":"Ann Intern Med"},{"issue":"13","key":"5838_CR17","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc"},{"key":"5838_CR18","unstructured":"Lopez-Lopez JA, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058."},{"key":"5838_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy807","author":"TF Chao","year":"2018","unstructured":"Chao TF, Chen SA, Ruff CT, et al. Clinical outcomes, Edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial[J]. Eur Heart J. 2018. https:\/\/doi.org\/10.1093\/eurheartj\/ehy807","journal-title":"Eur Heart J"},{"issue":"2","key":"5838_CR20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"5","key":"5838_CR21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"4","key":"5838_CR22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on control of anticoagulation of the scientific and standardization Committee of the International Society on thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"key":"5838_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07332-0","author":"S Wu","year":"2022","unstructured":"Wu S, Huang N, Chen X, et al. Association between body mass index and clinical outcomes in patients with Non-valvular atrial fibrillation receiving direct oral anticoagulants: A new piece of evidence on the obesity paradox from China. Cardiovasc Drugs Ther. 2022. https:\/\/doi.org\/10.1007\/s10557-022-07332-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"5838_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","volume":"3","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):28\u201336. https:\/\/doi.org\/10.1093\/ehjcvp\/pvw031. Epub 2016 Sep 27. PMID: 27680880; PMCID: PMC5216196.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"5838_CR25","doi-asserted-by":"publisher","first-page":"1125576","DOI":"10.3389\/fphar.2023.1125576","volume":"14","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, De Backer TL, Bertels X, Steurbaut S, Lahousse L. Long-term comparative effectiveness and safety of Dabigatran, Rivaroxaban, Apixaban and Edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. https:\/\/doi.org\/10.3389\/fphar.2023.1125576. PMID: 36817122; PMCID: PMC9932194.","journal-title":"Front Pharmacol"},{"issue":"4","key":"5838_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/jcm8040554","volume":"8","author":"A Mitchell","year":"2019","unstructured":"Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: A systematic review and Meta-Analyses of observational studies. J Clin Med. 2019;8(4):554. https:\/\/doi.org\/10.3390\/jcm8040554. PMID: 31022899; PMCID: PMC6518135.","journal-title":"J Clin Med"},{"key":"5838_CR27","doi-asserted-by":"publisher","first-page":"583311","DOI":"10.3389\/fphar.2020.583311","volume":"11","author":"M Grymonprez","year":"2020","unstructured":"Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: A systematic review and Meta-Analysis. Front Pharmacol. 2020;11:583311. https:\/\/doi.org\/10.3389\/fphar.2020.583311. PMID: 33013422; PMCID: PMC7509201.","journal-title":"Front Pharmacol"},{"key":"5838_CR28","doi-asserted-by":"publisher","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, K\u00f6hlen BTG, Nierman MC, Koek HL, Hemels MEW, Huisman MV, Kruip M, Faber LM, Wiersma NM, Buding WF, Fijnheer R, Adriaansen HJ, Roes KC, Hoes AW, Rutten FH, Geersing GJ. Safety of switching from a vitamin K antagonist to a Non-Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2023 Aug 27. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066485. Epub ahead of print. PMID: 37634130.","DOI":"10.1161\/CIRCULATIONAHA.123.066485"},{"key":"5838_CR29","doi-asserted-by":"publisher","unstructured":"Carnicelli AP, Hong H, Connolly SJ et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex [published correction appears in Circulation. 2022;145(8):e640. https:\/\/doi.org\/10.1161\/CIR.0000000000001058]. Circulation.2022;145(4):242\u2013255. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355","DOI":"10.1161\/CIR.0000000000001058 10.1161\/CIRCULATIONAHA.121.056355"},{"issue":"3","key":"5838_CR30","doi-asserted-by":"publisher","first-page":"e022478","DOI":"10.1136\/bmjopen-2018-022478","volume":"9","author":"M Rohla","year":"2019","unstructured":"Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational prevention oF thromboembolic events - European registry in atrial fibrillation (PREFER in AF). BMJ Open. 2019;9(3):e022478. https:\/\/doi.org\/10.1136\/bmjopen-2018-022478. PMID: 30928922; PMCID: PMC6475354.","journal-title":"BMJ Open"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-05838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-05838-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-05838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:39:28Z","timestamp":1743093568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-025-05838-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5838"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-05838-4","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the Declaration of Helsinki and was authorized by The Ethics Committee of Fujian Maternal and Child Health Hospital (registration number: ChiCTR2300067734). The review committee waived informed consent of patient because of the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}